<DOC>
	<DOCNO>NCT01521923</DOCNO>
	<brief_summary>This study intend evaluate efficacy safety Certolizumab Pegol ( CZP ) combination Methotrexate ( MTX ) sustain clinical response achieve study RA0055 Period 1 [ NCT01519791 ] . Subjects enter study RA0055 Period 2 achieve sustain Low Disease Activity Week 52 study RA0055 Period 1 .</brief_summary>
	<brief_title>A Multi-center , Randomized , Double-blind , Placebo-controlled Study Evaluate Efficacy Safety Certolizumab Pegol Combination With Methotrexate Treatment Disease Modifying Antirheumatic Drugs ( DMARD ) -naïve Adults With Early Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Those subject previous study RA0055 Period 1 sustain LDA ( define DAS28 [ ESR ] ≤ 3.2 Weeks 40 52 ) Week 52 previous study RA0055 Period 1 Those subject previous study RA0055 Period 1 NOT sustain LDA ( define DAS28 [ ESR ] ≤ 3.2 Weeks 40 52 ) Week 52 previous study RA0055 Period 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Certolizumab Pegol - Cimzia</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>